NDA 210365 · Jazz Pharms Res
Epidiolex
Cannabidiol · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 25, 2018
Approved uses
4
Original approval plus efficacy supplements
Registered trials
462
100 Phase 3, 83 recruiting
FAERS reports
24,103
14,267 serious, 1,929 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2026.
EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )
Mechanism: The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2023 Supplement 20 · Efficacy OrphanLetterLabel
- Jul 31, 2020 Supplement 5 · Efficacy · priority review OrphanLabelLetterReview
- Jul 31, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetterReview
- Jun 25, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- EPIDIOLEX · CANNABIDIOL 100MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cannabidiol" as an intervention, any sponsor and status, largest first.
OMNI Medical Services, LLCResearch network
NCT03944447 · 200,000 participants (planned) · Start Dec 1, 2018 · Primary completion Dec 31, 2025
Drug: Cannabis, Medical · For: Chronic Pain; Chronic Pain Syndrome; Chronic Pain Due to Injury and 30 more
Sites: Boca Raton, Florida; Bradenton, Florida; Fort Lauderdale, Florida · 17 sites in all
- An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut SyndromesPivotal-lookingCompleted
GW Research LtdJazz Pharmaceuticals (JAZZ)
NCT02224573 · 681 participants · Start Jun 11, 2015 · Primary completion Sep 24, 2020
Drug: GWP42003-P · For: Epilepsy; Dravet Syndrome; Lennox-Gastaut Syndrome
- Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related PainPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01337089 · 660 participants · Start Jan 19, 2011 · Primary completion Jan 27, 2016
Drug: Nabiximols · For: Pain; Advanced Cancer
Sites: Phoenix, Arizona; El Cajon, California; Gilroy, California · 128 sites in all
- Stratification and Treatment in Early Psychosis Study - PROMOTEPivotal-lookingNot yet recruiting
University of OxfordAcademic, hospital or other
NCT07434973 · 586 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2029
Drug: Cannabidiol (CBD); Placebo · For: Clinical High Risk for Psychosis (CHR); Clinical High Risk for Psychosis; Clinical High Risk for Developing Psychosis
Sites: Vienna, Austria; Montreal, Canada; Turku, Finland · 19 sites in all
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00681538 · 572 participants · Start Jan 2008 · Primary completion Jan 2009
Drug: Sativex®; Placebo · For: Spasticity; Multiple Sclerosis
Sites: Cliftonville, United Kingdom
- Evaluating Efficacy and Safety of CBD TPM Capsules for Use in InsomniaPivotal-lookingActive, not recruiting
Avecho BiotechnologyIndustry
NCT05840822 · 519 participants (planned) · Start May 16, 2024 · Primary completion Sep 30, 2027
Drug: Cannabidiol (CBD) Capsule 75mg; Placebo · For: Insomnia
Sites: North Sydney, Australia; Sydney, Australia; Southport, Australia · 5 sites in all
- A Study of the Long-term Safety of Sativex UsePivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01606137 · 507 participants · Start Feb 2002 · Primary completion Dec 2004
Drug: GW-1000-02 · For: Multiple Sclerosis; Spasticity; Pain
Sites: Glasgow, United Kingdom
- Warrior CARE: Cannabis Behavioral HealthPivotal-lookingRecruiting
Wayne State UniversityAcademic, hospital or other
NCT06381180 · 500 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 31, 2030
Drug: Tetrahydrocannabinol; Cannabidiol and 1 more · For: Post Traumatic Stress Disorder; Cannabis Use; Suicide and 2 more
Sites: Detroit, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure6,169
- hospitalisation2,670
- off label use2,520
- product use in unapproved indication1,809
- diarrhoea1,776
- drug ineffective1,445
- death1,374
- somnolence1,340
- fatigue1,231
- product dose omission issue1,191
- weight decreased890
- weight increased845
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 3 |
| 2015 | 28 |
| 2016 | 35 |
| 2017 | 92 |
| 2018 | 232 |
| 2019 | 3,463 |
| 2020 | 3,556 |
| 2021 | 4,386 |
| 2022 | 3,787 |
| 2023 | 2,469 |
| 2024 | 2,045 |
| 2025 | 2,201 |
| 2026 | 1,805 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Epidiolex (Cannabidiol (Cbd))
2024 spending
$207M
Beneficiaries
4,517
43,893 claims
Per beneficiary
$45,925
$16.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $106,979,035 |
| 2021 | $140,129,330 |
| 2022 | $173,788,785 |
| 2023 | $197,357,912 |
| 2024 | $207,443,287 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis.
Barbeau-Grégoire M, Otis C, Cournoyer A, et al. · Int J Mol Sci 2022 · Meta-Analysis, Systematic Review
- Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis.
Han K, Wang JY, Wang PY, et al. · Psychiatry Res 2024 · Systematic Review, Meta-Analysis
- [Not Available].
Pinto JV, Saraf G, Frysch C, et al. · Can J Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD, Medeiros WMB, Santos JPMD, et al. · Trends Psychiatry Psychother 2024 · Randomized Controlled Trial
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Cannabinoid treatment for autism: a proof-of-concept randomized trial.
Aran A, Harel M, Cassuto H, et al. · Mol Autism 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.